Redefining the Standard in PE Care

The National Pulmonary Embolism Response Team (PERT) Consortium™ is again honored to host this supplement to Endovascular Today. The National PERT Consortium™, a 501(c)(3) organization founded in 2015, is the only multinational organization dedicated to the multidisciplinary, team-based approach in the treatment of pulmonary embolism (PE). Since its inception, The PERT Consortium™ has changed the landscape of PE treatment through innovative research, comprehensive guidelines, the largest and most in-depth registry, and the establishment of PERTs across the globe. This year marks a significant milestone for The Consortium™ as we celebrate 10 years of progress, life-saving initiatives, and a commitment to improving patient outcomes. As we continue to revolutionize PE care, we encourage the participation and input of individuals in allied health fields and welcome collaborative efforts benefitting PE patients.

In this supplement to Endovascular Today, readers will learn about the many and noteworthy National PERT Consortium™ initiatives, including the most impactful papers of the year, long-term management of the PERT patient, outcomes from the APEX-AV trial with the AlphaVac system (AngioDynamics, Inc.), the growth of PERTs throughout the world with PERT International, and the launch of our Trainee Council—a platform to engage trainees.

Showcasing the global reach of The PERT Consortium™, board members Drs. Ranade, Elder, and Konstantinides discuss PERT International and the ongoing efforts to improve outcomes around the world.

In addition, Drs. Keeling, Ranade, and Sokol highlight the recent findings from the APEX-AV study, which demonstrated both safety and efficacy of the AlphaVac multipurpose mechanical aspiration F18⁸⁵ system in patients who present with acute intermediate-risk PE. Their results support the use of this device in clinical practice and expand the available treatment options for the management of PE.

In their article on post-PE management, Drs. Khosla, Mina, and Samant discuss the importance of establishing follow-up care for patients who experience PE and outline the components and timeline of that care. Assessing the patient’s clinical status, anticoagulation adherence, symptom burden, and quality of life are important during the early follow-up visits and the steps of screening for post-PE impairment constituents are essential to address within a few months of PE diagnosis. Ultimately, the establishment of a post-PE care pathway aims to improve the morbidity and mortality associated with PE.

There have been many notable papers published in the last year, dealing with all manner of issues in acute PE. Here, Dr. Giri with the University of Pennsylvania and his coauthors showcase several of the most important, giving insights into gender-based outcome differences, high-risk PE, and costs across different health care systems.

In addition to our notable initiatives, The PERT Consortium™ will host the 10th Annual Pulmonary Embolism Scientific Symposium in Boston, Massachusetts, on September 12-14, 2024, where we are bringing together world thought leaders in the diagnosis, treatment, and research in PE. In addition to our symposium, we are pleased to announce our “Night to Inspire” Gala, which will take place on the evening of September 13th in Boston. The Gala will not only celebrate a decade of ground-breaking advancements in PE care and research, but also honor the visionary leadership and tireless dedication of Dr. Kenneth Rosenfield, Founder of The PERT Consortium™. We encourage everyone to attend this momentous occasion.

We remain honored to partner with Endovascular Today to host this annual supplement. We hope that the articles contained within reflect our passion and dedication to the treatment of PE. Please go to pertconsortium.org to learn more about us and how to join.